Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Any info about Iomega (IOM)? -- Ignore unavailable to you. Want to Upgrade?

To: Francis Muir who wrote (33226)	10/24/1997 10:57:00 AM
From: Markas	Respond to of 58324

Hi all. I've been lurking since 2/97, and finally paid my dues! Thanks to all for the great info. I hope I can provide some valuable insight, info, and analysis in the future. I've been in and out of IOM since '95. Rode it to the top, then down to 37 before bailing. Went long with a small stock purchase again in Jan or Feb '97 @ 17(still holding). Thanks to all I've learned from Truflette, Darrell,Jon, and others, I've also had 5 successful call option trades since 2/97. Just sold 1/2 of my Nov25s last Friday, and looking for another point or two to dump the rest. Thinking of the May25s on any pullback. Off thread - SR and FIDO, In June, a friend gave me a "hot tip" on a company she was researching for a broker, Zonagen(ZONA), which is also developing an oral ED drug named Vasomax(oral alprostadil). This stock was trading @ 28, with no earnings and at least 9-12 mos from applying for FDA approval. Currently @ 38(not a bad tip,butI didn't buy it). Instead, after reviewing the latest clinical trials available through Yahoo news, I purchased Macrochem(MCHM), which is working on a transdermal alprostadil gel. Simply rub on, then ready to have fun in 15-45min. Definitely kinder and gentler than a urethral suppository. There have been criticisms of this product on the VVUS threads such as "it can't work because alprostadil is too large to pass through the skin", however, this is exactly what MCHM specializes in, and no one has presented any evidence to counter the clinical trials as conducted by reputable MDs at major university hospitals. MCHM is also working on transdermal testosterone and ibuprofen, both of which will have enormous markets if perfected. The stock has recently run from 4 3/4 to 14 1/2 on no news. I'm in @5 13/16 and holding. I'd certainly apppreciate any thoughts on this issue. Let's bring it to the MCHM thread though, if interested.